International Society for Cardiovascular Translational Research

Legal name: Intl Soc For Cardiovascular Tran Res

Nonprofit profile at a glance

EIN
770682420
IRS 990 coverage
2015–2025
Official website data refreshed
Jul 2026
Forms available
Form 990 2025, Form 990-EZ 2024
Location
Phoenix, AZ, USA
Phone
+1 480.662.0722
Rating
69
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Heart, Circulatory Research

Official website

Reported finances

Revenue
$210,897
Expenses
$197,339
Assets
$386,292
Liabilities
$0

Source: IRS Form 990. Selected filing: tax year 2025. Amounts in USD.

Leadership & pay

28 people listed

Executive titles in this filing

  • DR NABIL DIB (President)
  • ANTHONY DEMARIA (Vice President)

People named in this filing

  • ROBERT BONOW (Director)
  • Tamara Syrek Jensen (Director)
  • STANTON ROWE (Director)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The Mission of ISCTR is to provide an environment for collaboration and guidance among academia (basic scientists, clinical scientists), industry, regulatory, reimbursement agencies, practice guidelines, and patients to expedite scientific discoveries into clinical application through the following: The development of translational pathways for cardiovascular devices, biologics, and drugs; Disseminating the science among the scientific community through the Journal of Cardiovascular Translational Research (JCTR); Developing training and certification in translational science.

What it reported doing in 2025

A summit, corresponding online courses, and an online journal, intended for physicians, medical device engineers, industry personnel, regulatory agencies, hospital administration, and reimbursement agencies titled, Translational Pathways for Cardiovascular Devices with the objective To Present and Discuss the Translational Pathways for Cardiovascular Diagnostic and Therapeutic Devices that Incorporates Input from Academia, Industry, FDA, and Payers. The sections included: 1. Device development processes, 2. Advances in high-risk coronary lesions, 3. Structural heart intervention Imaging, 4. Left appendage closure devices, 5. Pathways for heart failure, 6. Complex coronary occlusions.

Operating model

Revenue model
Donor-supported. 74% of the money available for current operations came from contributions and gifts.
Distribution model
Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.

The verdict

SUPPORTED - The filed numbers largely add up and most voting board members are independent. A relatively small share of available resources goes toward mission work and some filing-based governance responses are negative or unanswered.

Rating breakdown

  • Financial Efficiency: 59
  • Transparency & Controls: 92
  • Accountability: 76
  • Sustainability: 58
  • Growth: 0

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 58.1%; rating input score 58
  • Program expense ratio: 62.1%; rating input score 62
  • Fundraising efficiency: $19.77 raised per $1 spent on fundraising; rating input score 55; 55th percentile among comparable filings

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
  • Pay-setting controls: Limited
  • Foreign activity oversight: Limited
  • Grant itemization coverage: Limited
  • Major donor itemization: Yes; rating input score 100
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
  • Governance controls: 3 of 7 controls in place; rating input score 43
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Fail
    • Document-retention policy: Fail
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: NotApplicable
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Missing
    • Independent financial-statement audit: Fail

Sustainability

  • Operating margin: 6.4%; rating input score 50; 50th percentile among comparable filings
  • Total-asset coverage ratio: 1.96; rating input score 59; 59th percentile among comparable filings
  • Liabilities to assets ratio: 0; rating input score 77; 77th percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 67; 67th percentile among comparable filings

Growth

  • Program expense growth: -14% per year; rating input score 0; 8th percentile among comparable filings
  • Revenue growth: -17.3% per year; rating input score 0; 3rd percentile among comparable filings
  • Asset growth: -1.1% per year; rating input score 0; 18th percentile among comparable filings

Details

  • What they do: 6 programs and campaigns described on the official site
  • Where the money goes: 58.1% of revenue deployed · 62.1% of spending went to programs
  • Governance: 28 of 28 board members independent · 3 of 7 filing controls reported
  • Programs: 1 filed program accomplishment · $123K in reported program spending
  • Leadership: top reported pay $0 · 28 people listed
  • Consistency: 20 of 22 current checks pass · 2 findings to review
  • Schedules: 4 filed schedules · includes major donors
  • Filing history: 9 filing years from 2015 to 2025
  • Contacts: How to reach this organization
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Review — Financial Efficiency: Mission deployment rate scored 58/100.
  • Moderate — Accountability: Governance controls: 3 of 6 not reported.
  • High — Growth: Program expense growth scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • Review — Financial Efficiency: Fundraising efficiency scored 55/100.
  • Review — Sustainability: Operating margin scored 50/100.
  • Moderate — Transparency & Controls: Functional expense sum did not reconcile in the filed values.
  • Moderate — Transparency & Controls: Part IX DepreciationDepletion column sum did not reconcile in the filed values.
  • High — Growth: Asset growth scored 0/100.
  • Review — Sustainability: Total-asset coverage ratio scored 59/100.